974 results on '"Marcocci, C"'
Search Results
2. Conventional X-rays in the diagnosis and follow-up of vertebral fractures in patients with acromegaly: a real-life study
3. Clinical and molecular characteristics of two Italian kindreds with hypoparathyroidism, deafness and renal dysplasia (HDR) syndrome
4. In Graves’ disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features
5. Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
6. Sirolimus as a second-line treatment for Graves’ orbitopathy
7. Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism
8. Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment
9. Macro-PTH, a rare cause of unexplained elevated serum PTH levels
10. Teprotumumab for Graves’ orbitopathy and ototoxicity: moving problems from eyes to ears?
11. Renal complications and quality of life in postsurgical hypoparathyroidism: a case–control study
12. Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study
13. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy
14. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity
15. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study
16. Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?
17. Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis
18. Consensus statement from 2nd International Conference on Controversies in Vitamin D
19. Whole exome sequencing in familial isolated primary hyperparathyroidism
20. The Platform for Earth Observation from Space in the framework of the Italian PNRR - Next Generation EU
21. INGV Center for Space Observations of Earth (COS): Application Modules and ICT Platform
22. Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic
23. Vitamin D status and cardiovascular outcome
24. Measurement of urinary free cortisol by LC–MS–MS: adoption of a literature reference range and comparison with our current immunometric method
25. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy
26. Graves’ disease and Graves’ orbitopathy following COVID-19
27. Conventional X-rays in the diagnosis and follow-up of vertebral fractures in patients with acromegaly: a real-life study
28. Pan-Arctic GNSS INfrastructure for Atmospheric science: state of the art of the PAGINA project
29. Clinical and molecular characteristics of two Italian kindreds with hypoparathyroidism, deafness and renal dysplasia (HDR) syndrome
30. Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study
31. Clinical presentation and management of patients with primary hyperparathyroidism in Italy
32. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism
33. Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients
34. Occurrence of Graves’ hyperthyroidism and Graves’ orbitopathy after fine-needle aspiration biopsy of thyroid nodules
35. Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?
36. Familial and Hereditary Forms of Primary Hyperparathyroidism
37. Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment?
38. Graves’ orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein–Barr virus infection: a serological and molecular study
39. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?
40. Effects of selenium on short-term control of hyperthyroidism due to Graves’ disease treated with methimazole: results of a randomized clinical trial
41. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus
42. Correction to: Whole exome sequencing in familial isolated primary hyperparathyroidism
43. Acute severe primary hyperparathyroidism: spontaneous remission after 2 years follow-up
44. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves’ orbitopathy
45. Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis
46. Update on parathyroid carcinoma
47. The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis
48. Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
49. Total thyroid ablation in Graves’ orbitopathy
50. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.